CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target.
CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CBFA2T3-GLIS2(C/G)融合是一种隐性易位的产物,主要见于婴儿和幼儿期,并与不良预后相关。在此,我们证明C/G致癌融合蛋白的表达在人脐血造血干/祖细胞(CB HSPC)中促进了转化,这一过程发生在内皮细胞共培养系统中,该系统重现了C/G急性髓系白血病(AML)的转录组、形态学和免疫表型,并在异种移植模型中诱导了高度侵袭性白血病。通过分析C/G-CB细胞和原发性C/G AML的转录组,我们鉴定出一组C/G融合特异性基因,这些基因是潜在的治疗靶点。
我们针对其中一个靶点——叶酸受体(FOLR1)——开发了嵌合抗原受体(CAR)T细胞,并利用体外和异种移植模型证明了其针对C/G AML的临床前疗效。FOLR1也在肾和肺上皮中表达,这引发了对毒性的担忧,必须在该疗法的临床应用中加以解决。
我们的发现强调了内皮微环境在促进C/G转导的CB HSPC白血病转化中的作用。此外,这项工作对白血病发生研究具有广泛意义,适用于多种致癌融合驱动的儿童白血病,提供了一个稳健且易于操作的模型系统,用于表征白血病发生的分子机制,并鉴定疾病诊断的生物标志物和治疗靶点。
The CBFA2T3-GLIS2 (C/G) fusion is a product of a cryptic translocation primarily seen in infants and early childhood and is associated with dismal outcome.
Here, we demonstrate that the expression of the C/G oncogenic fusion protein promotes the transformation of human cord blood hematopoietic stem and progenitor cells (CB HSPCs) in an endothelial cell coculture system that recapitulates the transcriptome, morphology, and immunophenotype of C/G acute myeloid leukemia (AML) and induces highly aggressive leukemia in xenograft models. Interrogating the transcriptome of C/G-CB cells and primary C/G AML identified a library of C/G-fusion-specific genes that are potential targets for therapy.
We developed chimeric antigen receptor (CAR) T cells directed against one of the targets, folate receptor (FOLR1), and demonstrated their preclinical efficacy against C/G AML using in vitro and xenograft models. FOLR1 is also expressed in renal and pulmonary epithelium, raising concerns for toxicity that must be addressed for the clinical application of this therapy.
Our findings underscore the role of the endothelial niche in promoting leukemic transformation of C/G-transduced CB HSPCs.
Furthermore, this work has broad implications for studies of leukemogenesis applicable to a variety of oncogenic fusion-driven pediatric leukemias, providing a robust and tractable model system to characterize the molecular mechanisms of leukemogenesis and identify biomarkers for disease diagnosis and targets for therapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。